Ovarian cancer study halted: lab test may help match patients to targeted drug
NCT ID NCT04780945
First seen Feb 18, 2026 · Last updated May 01, 2026 · Updated 7 times
Summary
This study looked at a lab test called the RAD51 assay to see if it could identify which patients with recurrent ovarian cancer would respond to the drug olaparib. The test checks for a specific DNA repair problem in tumor cells. The study was terminated early, but it aimed to find a better way to match patients to this targeted treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HOMOLOGOUS RECOMBINATION DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Erasmus Medical Center
Rotterdam, Netherlands
-
Leiden University Medical Center
Leiden, 2300RC, Netherlands
-
University Medical Center Groningen
Groningen, Netherlands
Conditions
Explore the condition pages connected to this study.